These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33506892)

  • 1. Differences in biologics for treating ankylosing spondylitis: the contribution of network meta-analysis.
    Migliore A; Gigliucci G; Integlia D; Isailovic N; Frediani B
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):56-64. PubMed ID: 33506892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Survival of Biologics in Treating Ankylosing Spondylitis: A Systematic Review and Meta-analysis of Real-World Evidence.
    Yu CL; Yang CH; Chi CC
    BioDrugs; 2020 Oct; 34(5):669-679. PubMed ID: 32946076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect comparison between subcutaneous biologic agents in ankylosing spondylitis.
    Migliore A; Bizzi E; Bernardi M; Picchianti Diamanti A; Laganà B; Petrella L
    Clin Drug Investig; 2015 Jan; 35(1):23-9. PubMed ID: 25388909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials.
    Gensler LS; Chakravarty SD; Cameron C; Peterson S; Spin P; Kafka S; Nair S; Deodhar A
    Clin Rheumatol; 2020 Oct; 39(10):2907-2917. PubMed ID: 32367407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indirect comparison of the effects of anti-TNF biological agents in patients with ankylosing spondylitis by means of a mixed treatment comparison performed on efficacy data from published randomised, controlled trials.
    Migliore A; Broccoli S; Bizzi E; Laganà B
    J Med Econ; 2012; 15(3):473-80. PubMed ID: 22335398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis.
    Wang R; Dasgupta A; Ward MM
    J Rheumatol; 2018 Apr; 45(4):481-490. PubMed ID: 29335342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Jain M; Jugl SM
    J Med Econ; 2019 Jan; 22(1):45-52. PubMed ID: 30346844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N; Lee YC; Shah N; Harrison DJ
    Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review and network meta-analysis of current and investigational treatments for active ankylosing spondylitis.
    Deodhar A; Chakravarty SD; Cameron C; Peterson S; Hensman R; Fogarty S; Spin P; Kafka S; Nair S; Gensler LS
    Clin Rheumatol; 2020 Aug; 39(8):2307-2315. PubMed ID: 32107666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis.
    Betts KA; Griffith J; Song Y; Mittal M; Joshi A; Wu EQ; Ganguli A
    Rheumatol Ther; 2016 Dec; 3(2):323-336. PubMed ID: 27747581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Efficacy and Acceptability of Anti-TNF-Alpha Therapy in Ankylosing Spondylitis: A Mixed-Treatments Comparison.
    Wang Y; Wang H; Jiang J; Zhao D; Liu Y
    Cell Physiol Biochem; 2016; 39(5):1679-1694. PubMed ID: 27643888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
    Chastek B; White J; Van Voorhis D; Tang D; Stolshek BS
    Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model-Based Meta-Analysis in Ankylosing Spondylitis: A Quantitative Comparison of Biologics and Small Targeted Molecules.
    Wu Y; Feng X; Li J; Wang X; Yang C; Zhao L
    Clin Pharmacol Ther; 2019 May; 105(5):1244-1255. PubMed ID: 30450610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis.
    Baji P; Péntek M; Szántó S; Géher P; Gulácsi L; Balogh O; Brodszky V
    Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S45-52. PubMed ID: 24832835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
    Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
    Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Comparative Safety of TNF Inhibitors in Ankylosing Spondylitis-a Meta-Analysis Update of 14 Randomized Controlled Trials.
    Hou LQ; Jiang GX; Chen YF; Yang XM; Meng L; Xue M; Liu XG; Chen XC; Li X
    Clin Rev Allergy Immunol; 2018 Apr; 54(2):234-243. PubMed ID: 28717941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of continuation rates with three TNFα antagonists (adalimumab, infliximab, etanercept) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: Retrospective 10-year study.
    Batteux B; Devauchelle A; Boyard PL; Sejourné A; Fardellone P; Goëb V
    Joint Bone Spine; 2016 Oct; 83(5):607-9. PubMed ID: 26919803
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
    Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
    J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.